Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

Cancer Immunology Immunotherapy

Volumn 49, Issue 9, 2000, Pages 504-514

  Hörig, Heidi ^a   Lee, David S ^a   Conkright, William ^a   Divito, Joe ^a   Hasson, Henry ^a   LaMare, Michelle ^a   Rivera, Audrey ^a   Park, David ^a   Tine, John ^b   Guito, Ken ^c   Tsang, Kwong Wong Yok ^d   Schlom, Jeffrey ^d   Kaufman, Howard L ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b Virogenetics Corporation   (United States)

^c Pasteur Merieux Connaught   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinoembryonic antigen; Costimulation; Poxvirus; Tumor vaccine

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR VACCINE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; PHASE 1 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD80; AVIPOXVIRUS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE; CELLS, CULTURED; COHORT STUDIES; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; LUNG NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDES; PHENOTYPE; RECTAL NEOPLASMS; STOMACH NEOPLASMS; T-LYMPHOCYTES; TIME FACTORS;

EID: 0033766694     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000146     Document Type: Article

References (42)

1. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia virus expressing a modified MUC-1 gene and the murine T cell costimulatory molecule B7
2. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
3. CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer
4. New perspectives of CD28-B7-mediated T cell costimulation
5. Purification of a factor required for transcription of vaccinia virus early genes
6. Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge
7. Human B7-1 is more efficient than B7-2 in providing costimulation for alloantigen-specific T cells
8. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
9. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
10. + T lymphocytes in the P815 tumor system in vitro
11. Carcinoembryonic antigen in histopathology: Immunoperoxidase staining of conventional tissue sections
12. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T cell responses and antitumor immunity
13. Human cytotoxic T-lymphocyte repertoire to influenza A viruses
14. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
15. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule
16. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
17. + T cells and induce similar patterns of cytokine secretion in vitro
18. Costimulatory approaches to adoptive immunotherapy
19. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
20. Tolerance, danger, and the extended family
21. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer
22. Antinuclear antibodies and elevated anti-Epstein-Barr virus titers in cancer patients
23. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE
24. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
25. The anatomical basis of intestinal immunity
26. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues
27. Genetically modified tumor vaccines - Where we are today
28. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte
29. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases
30. Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation
31. Identification of the genes encoding cancer antigens: Implications for cancer immunotherapy
32. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized With recombinant carcinoembryonic antigen
33. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay
34. Differential expression of B7 costimulatory molecules by astrocytes correlates with T cell activation and cytokine production
35. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
36. + T cells by B7-transfected melanoma cells
37. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
38. Phase I trial with ALVAC-CEA-B7.1 immunization in advanced CEA-expressing adenocarcinomas
39. Human tumor antigens: Implications for cancer vaccine development
40. The role of B7-CD28 costimulation in tumor rejection
41. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen
42. Specific cytolytic T cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine